Newbury Pharmaceuticals Q1 Report: Ramp-up in sales - Redeye

Redeye provides a research update following the Q1 report published by Newbury yesterday. We make some upward adjustments to our estimates for future sales growth following stronger sales figures than anticipated. Accordingly, we raise our fair value base case valuation to SEK9 (8.5).

Länk till analysen i sin helhet: https://www.redeye.se/research/970224/newbury-pharmaceuticals-q1-report-ramp-up-in-sales?utm_source=finwire&utm_medium=RSS